Results 291 to 300 of about 5,782,005 (384)

Monoclonal immunoglobulin measurement by mass spectrometry in patients with multiple myeloma and kidney failure: Analysis from the EuLITE trial. [PDF]

Br J Haematol
McIlroy G, Giles HV, Rollins A, Malin G, Jones L, Wright NJ, Berlanga O, North S, Cook M, Hutchison C, Heyne N, Weisel K, Pinney J, Harding S, Cockwell P, Pratt G.   +15 more
europepmc   +1 more source

ZIP10 as a potential therapeutic target in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Increased intracellular zinc levels in acute myeloid leukaemia blasts with upregulated expression of zinc influx transporters ZIP6 and ZIP10. Targeting ZIP10 with a surface antibody represents a potential therapeutic strategy. Created in BioRender. Rolles, B. (2025) https://BioRender.com/bwrtof1.
Benjamin Rolles, Nicolas Chatain, Richard Görg, Margherita Vieri, Nora Tillmann‐Tröster, Marcel G. Bourgeois, Deborah Christen, Jeanette Walter, Addison C. Hillerbrand, Kyle A. Romine, Kathryn M. Taylor, Jens Bertram, Edgar Jost, Steffen Koschmieder, Fabian Beier, Maximilian Stahl, Tim H. Brümmendorf, Lothar Rink, Inga Wessels   +18 more
wiley   +1 more source

PROTEINS IN MULTIPLE MYELOMA

Journal of Biological Chemistry, 1957
Frank W. Putnam, Aiko Miyake
openaire   +3 more sources

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]

, 2018
et al,, Stockerl-Goldstein, Keith E, Vij, Ravi   +2 more
core   +1 more source

Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T‐cell (CAR‐T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CAR‐T for relapsed/refractory large B‐cell lymphoma. Among 155 patients, 28 (18%) developed AKI with a median time‐to‐
John Sharp, Qiuhong Zhao, Timothy J. Voorhees, David A. Bond, Yazeed Sawalha, John Reneau, Audrey Sigmund, Walter Hanel, Lalit Sehgal, Lapo Alinari, Robert Baiocchi, Jonathan E. Brammer, Kami Maddocks, Beth Christian, Evandro Bezerra, Nathan Denlinger, Sumithira Vasu, Marcos De Lima, Jason Prosek, Narendranath Epperla   +19 more
wiley   +1 more source

A quantum machine learning framework for predicting drug sensitivity in multiple myeloma using proteomic data. [PDF]

Sci Rep
Priyadharshini M, Raju BD, Banu AF, Kumar PJ, Murugesh V, Rybin O.   +5 more
europepmc   +1 more source

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy [PDF]

, 2019
Azab, Abdel Kareem, Azab, Feda, Fiala, Mark, Fogler, William E., King, Justin, Kohnen, Daniel, Magnani, John L., Muz, Barbara, Smith, Ted, Vij, Ravi   +9 more
core   +1 more source

Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapy

British Journal of Haematology, EarlyView.
During febrile neutropenia in patients with haematological malignancies, pentraxin 3 (PTX3), a soluble innate immunity receptor, increases with severe sepsis, while clusterin, a chaperon protein involved in extracellular histones clearance, decreases in patients with quick SOFA score (qSOFA) ≥2.
Coralie Mallebranche, Carole Mosnier, Corentin Orvain, Jérémie Riou, Sylvain Thepot, Pascale Pignon, Simon Blanchard, Nathalie Tortevoie, Isabelle Pellier, Mathilde Hunault‐Berger, Pascale Jeannin, Yves Delneste, Aline Schmidt‐Tanguy, Céline Beauvillain   +13 more
wiley   +1 more source

Vacuolar myopathy associated with lambda light chain myeloma: a case report and review of the literature. [PDF]

BMC Musculoskelet Disord
de Berny Q, Salle V, Renard C, Merle PE, Guilain N, Choukroun G, Morel P, Fourdinier O.   +7 more
europepmc   +1 more source

Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma

British Journal of Haematology, EarlyView.
Translational analyses from the KarMMa trial (NCT03361748) highlight that baseline tumour burden, immune environment and chimeric antigen receptor (CAR) T‐cell dynamics influence both the initiation and durability of response to idecabtagene vicleucel (ide‐cel) in relapsed and refractory multiple myeloma.
Nathan Martin, Ethan Thompson, Nicholas Stong, Yang Xu, Olivia Finney, Julie Rytlewski, Erin Flynt, Jessica Marfo, Dante B. Descalzi‐Montoya, Irene Manrique, Bruno Paiva, Nikhil Munshi, Timothy B. Campbell, Shari M. Kaiser   +13 more
wiley   +1 more source